Formoterol for diabetic kidney disease
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes.
- Your kidney function is moderately reduced (stage 2 to 3b chronic kidney disease).
- You have elevated protein in your urine (albumin-to-creatinine ratio between 200 and 5000).
- You are already taking a standard diabetes or blood pressure medication (like an ACE inhibitor, ARB, or SGLT2 inhibitor).
- You are not currently using beta-agonist inhalers (like those for asthma) and do not have asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
This trial tests if a new drug, R3R01, can help reduce protein leaking into the urine in people with diabetic kidney disease. It may offer a new option for managing kidney health.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This trial tests whether a common asthma medication (montelukast) can help protect kidney, heart, and eye health in people with type 2 diabetes and early kidney problems. The study aims to see if the drug can slow down kidney damage and improve overall health.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
Hear when a new Diabetic Nephropathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.